The problems with anticancer therapy are resistance and toxicity. From 3000 Cisplatin
derivatives tested as antitumor agents, most of them have been rejected, due to toxicity. The …

Background Brentuximab vedotin (BV) is an antibody-drug conjucate (ADC) comprising a
CD30-directed antibody, conjugated to the microtubule-disrupting agent MMAE via a …

Prognosis in patients suffering from high‐risk, refractory and relapsed germ cell tumours
(GCT) often comprising of CD 30‐positive embryonal carcinoma (EC) components remains …

T‐cell lymphoproliferative disorders are a heterogeneous group of neoplasms with distinct
clinical‐biological properties. The normal cellular counterpart of these processes has been …

A major limitation to current cancer therapies is the development of therapy-related side-
effects and dose limiting complications. Moreover, a better understanding of the biology of …

Non‐Hodgkin lymphomas (NHLs) are a heterogeneous group of hematologic malignancies
which typically respond to standard first‐line chemoimmunotherapy regimens. Unfortunately …

Pediatric anaplastic large-cell lymphoma (ALCL), which is characterized by strong
expression of CD30, is usually responsive to multidrug chemotherapy. Brentuximab vedotin …

间变大细胞淋巴瘤(anaplastic large cell lymphoma, ALCL) 是一种罕见的, 侵袭性较强的CD30
阳性T 细胞淋巴瘤. 根据间变性淋巴瘤激酶(anaplastic lymphoma kinase, ALK) 的表达状态 …

The term anaplastic large cell lymphoma (ALCL) was first coined by Stein et al.[1] in 1985 to
describe a particular type of lymphoma characterized by a proliferation of neoplastic …

Этиология периферических нодальных Т-клеточных лимфом остается недостаточно
изученной [2], однако некоторые нозологические формы напрямую связаны с …